RETROSPECTIVE SURVEY FOR HEPATITIS B VIRUS REACTIVATION DURING IMMUNOSUPPRESSIVE THERAPIES FOR RHEUMATOID WITH ADMINISTRATIVE DATA

Author(s)

Imai S1, Yamana H2, Akazawa M3, Fushimi K4, Migita K5, Yatsuhashi H6
1National Hospital Organization Headquarters, Tokyo, Japan, 2The University of Tokyo, Tokyo, Japan, 3Meiji Pharmaceutical University, Tokyo, Japan, 4Tokyo Medical and Dental University Graduate School, Tokyo, Japan, 5Fukushima Medical University, Fukushima, Japan, 6National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan

OBJECTIVES

Risk of hepatitis B virus (HBV) reactivation has increased because of advances in immunosuppressive therapies. People having a previously-resolved HBV infection and those with serum HBs-antigen positivity are likely to develop liver injuries after the therapies. However, the risk of HBV reactivation for rheumatoid arthritis (RA) patients is still unclear. This study described a validity of detecting prHBV infection from administrative data by comparing with chart abstraction, and to determine an incidence of HBV reactivation during immunosuppressive therapy of Japanese RA patients.

METHODS

Adult patients who had been diagnosed with RA between 1 April 2011 and 31 March 2015 were extracted from the Medical Information Analysis (MIA) databank managed by the Clinical Research Center at the National Organization Hospitals (NHO) Headquarters. We also conducted chart abstraction in three hospitals to verify whether those patients actuary had records of prHBV infection, de novo hepatitis, and HBsAg carriers. A positive predictive value (PPV) of the algorithm of HBV-DNA testing with immunosuppressive therapy performed four times or more / year for the detection of prHBV infection from administrative data and an incidence rate of HBV reactivation among preHBV infections during immunosuppressive therapy for RA were calculated.

RESULTS

The PPV and its 95% confidence interval (CI) of administrative data for the identification of suspected prHBV infections was 85.8% (95% CI: 81.7% - 89.3%). The incidence rate of de novo hepatitis was 1.23 / 100 person-years.

CONCLUSIONS

The main concerns of epidemiological studies using administrative health data are lack of health information to identify true patients and the validity of recorded diagnoses and other information is critical. For HBV reactivation, monitoring data of serum HBV-DNA levels after immunosuppressive therapies were unavailable in the database and the chart review was useful approach. This validity study provided a good example to help our future HBV projects.

Conference/Value in Health Info

2019-11, ISPOR Europe 2019, Copenhagen, Denmark

Code

PIN149

Topic

Real World Data & Information Systems

Topic Subcategory

Health & Insurance Records Systems

Disease

Infectious Disease (non-vaccine), Musculoskeletal Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×